1. Home
  2. BWA vs ABVX Comparison

BWA vs ABVX Comparison

Compare BWA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BorgWarner Inc.

BWA

BorgWarner Inc.

HOLD

Current Price

$47.75

Market Cap

9.2B

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$118.78

Market Cap

9.0B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWA
ABVX
Founded
1987
2013
Country
United States
France
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
9.2B
9.0B
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
BWA
ABVX
Price
$47.75
$118.78
Analyst Decision
Buy
Strong Buy
Analyst Count
14
12
Target Price
$46.93
$115.83
AVG Volume (30 Days)
3.4M
1.8M
Earning Date
02-05-2026
08-11-2025
Dividend Yield
1.43%
N/A
EPS Growth
N/A
N/A
EPS
0.61
N/A
Revenue
$14,183,000,000.00
$6,231,374.00
Revenue This Year
$1.96
$6.80
Revenue Next Year
$2.53
N/A
P/E Ratio
$77.98
N/A
Revenue Growth
0.10
N/A
52 Week Low
$24.40
$4.77
52 Week High
$47.68
$148.83

Technical Indicators

Market Signals
Indicator
BWA
ABVX
Relative Strength Index (RSI) 69.18 45.04
Support Level $45.04 $129.89
Resistance Level $46.23 $138.69
Average True Range (ATR) 0.86 6.99
MACD 0.26 -1.62
Stochastic Oscillator 94.93 25.44

Price Performance

Historical Comparison
BWA
ABVX

About BWA BorgWarner Inc.

BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: